Clinical Trial Update: SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial [Phase 2]

View source ↗

Summary

Phase 2 trial SPIRITT evaluated second-line panitumumab plus irinotecan in colon/colorectal cancer; results have been posted following completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• panitumumab + irinotecan

Snippet

Sponsor: Amgen | Conditions: Cancer, Colon Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-03-28